Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Streamlines Upper Management; Katen Positioned As Heir Apparent

Executive Summary

Pfizer's newly created corporate executive committee streamlines the company's top management structure

You may also be interested in...



Pfizer’s Shedlarz retires

Pfizer Vice Chairman David Shedlarz will retire at the end of the year, the company announces Oct. 25. Shedlarz was considered a potential successor to then-CEO Hank McKinnell when he was promoted to vice chairman, along with Karen Katen and current CEO Jeffrey Kindler in 2006 (1"The Pink Sheet" Feb. 28, 2005, p. 20). Shedlarz is noted for leading the integration of the Pharmacia acquisition in 2003, which has been a challenge for Pfizer (2"The Pink Sheet" July 22, 2002, p. 3). Shedlarz joined the company in 1976; he served 10 years as CFO, and most recently led strategic planning and business development...

Pfizer’s Shedlarz retires

Pfizer Vice Chairman David Shedlarz will retire at the end of the year, the company announces Oct. 25. Shedlarz was considered a potential successor to then-CEO Hank McKinnell when he was promoted to vice chairman, along with Karen Katen and current CEO Jeffrey Kindler in 2006 (1"The Pink Sheet" Feb. 28, 2005, p. 20). Shedlarz is noted for leading the integration of the Pharmacia acquisition in 2003, which has been a challenge for Pfizer (2"The Pink Sheet" July 22, 2002, p. 3). Shedlarz joined the company in 1976; he served 10 years as CFO, and most recently led strategic planning and business development...

McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale

Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said

Related Content

Topics

UsernamePublicRestriction

Register

PS045441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel